About
Incyte Corporation (NASDAQ:INCY) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
Apr 2 2026
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Mar 28 2026
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Mar 25 2026
Incyte Announces Executive Leadership Appointments
Mar 20 2026
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Financials
Revenue
$5.14 B
Market Cap
$19.09 B
P/E Ratio
14.97
EPS
6.41
Translate